Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Assets (2017 - 2025)

Autolus Therapeutics' Current Assets history spans 9 years, with the latest figure at $435.9 million for Q4 2025.

  • For Q4 2025, Current Assets fell 34.05% year-over-year to $435.9 million; the TTM value through Dec 2025 reached $435.9 million, down 34.05%, while the annual FY2025 figure was $435.9 million, 34.05% down from the prior year.
  • Current Assets reached $435.9 million in Q4 2025 per AUTL's latest filing, down from $514.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $804.3 million in Q1 2024 to a low of $212.3 million in Q3 2022.
  • Average Current Assets over 5 years is $468.8 million, with a median of $425.8 million recorded in 2022.
  • Peak YoY movement for Current Assets: crashed 35.34% in 2023, then skyrocketed 140.07% in 2024.
  • A 5-year view of Current Assets shows it stood at $347.0 million in 2021, then rose by 22.72% to $425.8 million in 2022, then plummeted by 35.34% to $275.3 million in 2023, then surged by 140.07% to $660.9 million in 2024, then plummeted by 34.05% to $435.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Current Assets are $435.9 million (Q4 2025), $514.6 million (Q3 2025), and $574.2 million (Q2 2025).